These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 23427943

  • 21. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L, Qiu H, Zhang M, Zhang F, Yang H, Yang L, Jia L, Qin K, Jia L, Dou X, Cheng L, Sang M, Zhang C, Shan B, Zhang Z.
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [Abstract] [Full Text] [Related]

  • 22. A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.
    Stoleriu MG, Steger V, Mustafi M, Michaelis M, Cinatl J, Schneider W, Nolte A, Kurz J, Wendel HP, Schlensak C, Walker T.
    Eur J Cardiothorac Surg; 2014 Nov; 46(5):877-86. PubMed ID: 24627437
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
    Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW.
    Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
    Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ, Niu ZF.
    Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
    Zhang R, Chen X, Fu S, Xu L, Lin J.
    Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells.
    Tezcanli Kaymaz B, Bozok Cetintas V, Eroglu Z, Kosova B.
    J BUON; 2014 Sep; 19(1):145-52. PubMed ID: 24659656
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation.
    Choi JY, Lee S, Yun SM, Suh DH, Kim K, No JH, Jeong EH, Kim YB.
    Nutr Cancer; 2018 Jan; 70(1):109-115. PubMed ID: 29111786
    [Abstract] [Full Text] [Related]

  • 37. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.
    Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV.
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):681-9. PubMed ID: 18587580
    [Abstract] [Full Text] [Related]

  • 38. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Shi L, Yu H, Zhang W, Li L, Wang Q.
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.